
    
      This is an open-label study in patients who are currently using either a topical
      prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin
      plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the
      same eye(s). Compliance will be measured over the two months of participation.
    
  